Cargando…
Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
BACKGROUND: Several biomarkers of gemcitabine effectiveness have been studied in cancers, but less so in hepatocellular carcinoma (HCC), which is identified as the fifth most common cancer worldwide. Investigation of human equilibrative nucleoside transporter‐1 (HENT‐1) and deoxycytidine kinase (DCK...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676182/ https://www.ncbi.nlm.nih.gov/pubmed/32671914 http://dx.doi.org/10.1002/jcla.23457 |
_version_ | 1783611718675464192 |
---|---|
author | Attia, Fadia Fathy, Sara Anani, Maha Hassan, Adel Attia, Fawzy Ibrahim, Gehan Elazab, Mona |
author_facet | Attia, Fadia Fathy, Sara Anani, Maha Hassan, Adel Attia, Fawzy Ibrahim, Gehan Elazab, Mona |
author_sort | Attia, Fadia |
collection | PubMed |
description | BACKGROUND: Several biomarkers of gemcitabine effectiveness have been studied in cancers, but less so in hepatocellular carcinoma (HCC), which is identified as the fifth most common cancer worldwide. Investigation of human equilibrative nucleoside transporter‐1 (HENT‐1) and deoxycytidine kinase (DCK), genes involved in gemcitabine uptake and metabolism, can be beneficial in the selection of potential cancer patients who could be responding to the treatment. AIM: To study HENT‐1 and DCK gene expression in HCC patients with different protocols of treatment. METHODS: Using real‐time PCR, we analyzed expression levels of HENT‐1 and DCK genes from peripheral blood samples of 109 patients (20 controls & 89 HCC patients) between March 2015 and March 2017. All the 89 HCC patients received the antioxidants selenium (Se) and vitamin E (Vit.E) either alone (45 patients) or in combination with gemcitabine (24 patients) or radiofrequency ablation (RFA) (20 patients). RESULTS: There was a significant increase in HENT‐1 expression levels in HCC patients treated with Se and Vit.E alone as compared to controls (P ˂ .0001), while there was no significant difference between HCC patients treated with gemcitabine or RFA as compared to controls. In contrast, expression of DCK was significantly increased in all groups of HCC patients as compared to controls (P ˂ .0001). CONCLUSIONS: HENT‐1 and DCK mRNA expressions are important markers of HCC and for GEM effect and GEM sensitivity in patients with HCC. This could be beneficial in the selection of HCC patients sensitive to gemcitabine to avoid subjecting resistant patients to unnecessary chemotherapy. |
format | Online Article Text |
id | pubmed-7676182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76761822020-11-24 Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma Attia, Fadia Fathy, Sara Anani, Maha Hassan, Adel Attia, Fawzy Ibrahim, Gehan Elazab, Mona J Clin Lab Anal Research Articles BACKGROUND: Several biomarkers of gemcitabine effectiveness have been studied in cancers, but less so in hepatocellular carcinoma (HCC), which is identified as the fifth most common cancer worldwide. Investigation of human equilibrative nucleoside transporter‐1 (HENT‐1) and deoxycytidine kinase (DCK), genes involved in gemcitabine uptake and metabolism, can be beneficial in the selection of potential cancer patients who could be responding to the treatment. AIM: To study HENT‐1 and DCK gene expression in HCC patients with different protocols of treatment. METHODS: Using real‐time PCR, we analyzed expression levels of HENT‐1 and DCK genes from peripheral blood samples of 109 patients (20 controls & 89 HCC patients) between March 2015 and March 2017. All the 89 HCC patients received the antioxidants selenium (Se) and vitamin E (Vit.E) either alone (45 patients) or in combination with gemcitabine (24 patients) or radiofrequency ablation (RFA) (20 patients). RESULTS: There was a significant increase in HENT‐1 expression levels in HCC patients treated with Se and Vit.E alone as compared to controls (P ˂ .0001), while there was no significant difference between HCC patients treated with gemcitabine or RFA as compared to controls. In contrast, expression of DCK was significantly increased in all groups of HCC patients as compared to controls (P ˂ .0001). CONCLUSIONS: HENT‐1 and DCK mRNA expressions are important markers of HCC and for GEM effect and GEM sensitivity in patients with HCC. This could be beneficial in the selection of HCC patients sensitive to gemcitabine to avoid subjecting resistant patients to unnecessary chemotherapy. John Wiley and Sons Inc. 2020-07-16 /pmc/articles/PMC7676182/ /pubmed/32671914 http://dx.doi.org/10.1002/jcla.23457 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Attia, Fadia Fathy, Sara Anani, Maha Hassan, Adel Attia, Fawzy Ibrahim, Gehan Elazab, Mona Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma |
title | Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma |
title_full | Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma |
title_fullStr | Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma |
title_full_unstemmed | Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma |
title_short | Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma |
title_sort | human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in egyptian patients with hepatocellular carcinoma |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676182/ https://www.ncbi.nlm.nih.gov/pubmed/32671914 http://dx.doi.org/10.1002/jcla.23457 |
work_keys_str_mv | AT attiafadia humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma AT fathysara humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma AT ananimaha humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma AT hassanadel humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma AT attiafawzy humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma AT ibrahimgehan humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma AT elazabmona humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma |